Development of new treatment strategy against endometrial cancer targeting cancer assosiated fibroblast

• Project/Area Number: 24592507
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Kanazawa University
• Principal Investigator: MIZUMOTO Yasunari 金沢大学, 大学病院, 助教 (00420331)
• Co-Investigator(Kenkyū-buntansha): KYO Satoru 島根大学, 医学部, 教授 (50272969)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000); Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: 子宮内膜癌 / 癌線維芽細胞 / IGFBP6 / 子宮体癌 / CAF

Outline of Final Research Achievements

We investigeted the strategy to target cancer associated fibroblast(CAF) for endomertial cancer treatment.Analysis of clinical sample revieled decreased expression of secreatary protein,IGFBP6,in CAF. In vitro assay using cell lines also revieled IGF-2 dependent growth of endometrial cancer is canceled by addition of IGFBP6. This result suggest the possibility of inducing IGFBP6 in CAF as a new strategy to treat endometrial cancer.